<?xml version='1.0' encoding='utf-8'?>
<document id="25224009"><sentence text="The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme." /><sentence text="The binding and cytochrome P45051 (CYP51) inhibition properties of a novel antifungal compound, VT-1161, against purified recombinant Candida albicans CYP51 (ERG11) and Homo sapiens CYP51 were compared with those of clotrimazole, fluconazole, itraconazole, and voriconazole"><entity charOffset="216-228" id="DDI-PubMed.25224009.s2.e0" text="clotrimazole" /><entity charOffset="230-241" id="DDI-PubMed.25224009.s2.e1" text="fluconazole" /><entity charOffset="243-255" id="DDI-PubMed.25224009.s2.e2" text="itraconazole" /><entity charOffset="261-273" id="DDI-PubMed.25224009.s2.e3" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.25224009.s2.e0" e2="DDI-PubMed.25224009.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25224009.s2.e0" e2="DDI-PubMed.25224009.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25224009.s2.e0" e2="DDI-PubMed.25224009.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25224009.s2.e0" e2="DDI-PubMed.25224009.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25224009.s2.e1" e2="DDI-PubMed.25224009.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25224009.s2.e1" e2="DDI-PubMed.25224009.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25224009.s2.e1" e2="DDI-PubMed.25224009.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25224009.s2.e2" e2="DDI-PubMed.25224009.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25224009.s2.e2" e2="DDI-PubMed.25224009.s2.e3" /></sentence><sentence text=" VT-1161 produced a type II binding spectrum with Candida albicans CYP51, characteristic of heme iron coordination"><entity charOffset="97-101" id="DDI-PubMed.25224009.s3.e0" text="iron" /></sentence><sentence text=" The binding affinity of VT-1161 for Candida albicans CYP51 was high (dissociation constant [Kd], ≤ 39 nM) and similar to that of the pharmaceutical azole antifungals (Kd, ≤ 50 nM)"><entity charOffset="149-154" id="DDI-PubMed.25224009.s4.e0" text="azole" /></sentence><sentence text=" In stark contrast, VT-1161 at concentrations up to 86 μM did not perturb the spectrum of recombinant human CYP51, whereas all the pharmaceutical azoles bound to human CYP51"><entity charOffset="146-152" id="DDI-PubMed.25224009.s5.e0" text="azoles" /></sentence><sentence text=" In reconstitution assays, VT-1161 inhibited Candida albicans CYP51 activity in a tight-binding fashion with a potency similar to that of the pharmaceutical azoles but failed to inhibit the human enzyme at the highest concentration tested (50 μM)"><entity charOffset="157-163" id="DDI-PubMed.25224009.s6.e0" text="azoles" /></sentence><sentence text=" In addition, VT-1161 (MIC = 0" /><sentence text="002 μg ml(-1)) had a more pronounced fungal sterol disruption profile (increased levels of methylated sterols and decreased levels of ergosterol) than the known CYP51 inhibitor voriconazole (MIC = 0"><entity charOffset="44-50" id="DDI-PubMed.25224009.s8.e0" text="sterol" /><entity charOffset="134-144" id="DDI-PubMed.25224009.s8.e1" text="ergosterol" /><entity charOffset="177-189" id="DDI-PubMed.25224009.s8.e2" text="voriconazole" /><entity charOffset="184-195" id="DDI-PubMed.25224009.s8.e3" text="azole" /><pair ddi="false" e1="DDI-PubMed.25224009.s8.e0" e2="DDI-PubMed.25224009.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25224009.s8.e0" e2="DDI-PubMed.25224009.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25224009.s8.e0" e2="DDI-PubMed.25224009.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25224009.s8.e0" e2="DDI-PubMed.25224009.s8.e3" /><pair ddi="false" e1="DDI-PubMed.25224009.s8.e1" e2="DDI-PubMed.25224009.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25224009.s8.e1" e2="DDI-PubMed.25224009.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25224009.s8.e1" e2="DDI-PubMed.25224009.s8.e3" /><pair ddi="false" e1="DDI-PubMed.25224009.s8.e2" e2="DDI-PubMed.25224009.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25224009.s8.e2" e2="DDI-PubMed.25224009.s8.e3" /></sentence><sentence text="004 μg ml(-1))" /><sentence text=" Furthermore, VT-1161 weakly inhibited human CYP2C9, CYP2C19, and CYP3A4, suggesting a low drug-drug interaction potential" /><sentence text=" In summary, VT-1161 potently inhibited Candida albicans CYP51 and culture growth but did not inhibit human CYP51, demonstrating a &gt;2,000-fold selectivity" /><sentence text=" This degree of potency and selectivity strongly supports the potential utility of VT-1161 in the treatment of Candida infections" /><sentence text="" /></document>